Ricerca avanzata

Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2016 Giugno;58(2) > Panminerva Medica 2016 Giugno;58(2):160-6

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOPANMINERVA MEDICA

Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Periodicità: Trimestrale

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 2016 Giugno;58(2):160-6

 REVIEWS

Long noncoding RNA PVT1, a novel promising biomarker to predict lymph node metastasis and prognosis: a meta-analysis

Fang T. LIU 1, Qi Z. XUE 2, Zheng M. ZHU 1, Cheng QIU 1, Teng F. HAO 1, Pei Q. ZHU 1, Hong L. LUO 1

1 Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China; 2 Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing, China

BACKGROUND: Numerous studies have found that the expression levels of long noncoding RNA PVT1 (lncRNA PVT1) were elevated in cancerous tissue, which was significantly higher than those in adjacent noncancerous tissues or corresponding normal tissues. Overexpression of lncRNA PVT1 was correlated with lymph node metastasis and a poor prognosis in various cancers.
METHODS: This quantitative meta-analysis collected all relevant articles and explored the association of lncRNA PVT1 expression levels with lymph node metastasis and prognosis. The systematic search was conducted through multiple electronic databases (up to December 1, 2015). The meta-analysis was performed by using RevMan5.3 software and Stata SE12.0.
RESULTS: A total of 939 patients with cancer from 10 studies were included. The Meta-analysis results showed that cancer patients with high PVT1 have a strong trend for LNM (OR=2.05, 95%CI:0.97-4.30, P=0.06, random-effects model). Moreover, we found that cancer patients with high PVT1 expression had a poorer overall survival (HR=2.07, 95%CI:1.40-2.74, P=0.000, fixed-effects model), a shorter recurrence-free survival (HR=1.70, 95%CI:1.02-2.39, P=0.000, fixed-effects model), and a worse disease-free survival (HR:2.10, 95%CI:0.96-3.23, P=0.000, fixed-effects model).
CONCLUSIONS: PVT-1 may serve as a novel molecular marker for lymph node metastasis and prognosis.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina